FDA approves Pfizer’s Tukysa regimen for metastatic breast cancer
Regulatory clearance was based on findings from the double-blind, placebo-controlled Phase III HER2CLIMB-05 trial.
Drug Development
10x Genomics and Fred Hutch partner on cancer technologies
Rocket receives $150m credit facility to advance cardiovascular portfolio
Gilead Sciences signs five-year DevOps agreement with Cognizant
Pacira partners with Molteni for Exparel commercialisation
AstraZeneca opens new R&D centre in Cambridge, US
FDA approves expanded indication for Lilly’s Jaypirca
Bayer plans $2.2bn pharmaceutical manufacturing facility in Ohio, US
